CD19 and diffuse large B-cell lymphoma: Clinical evidence indicates that 60%–70% of r/r DLBCL patients treated with CD19 CAR-T-cell therapy either do not achieve remission or experience relapse, with ~30% of such cases attributed to antigen loss [19, 26, 27].